According to reports from The Economic Times, Artemis Medicare Services shares have gained 26% over the past three months, significantly outperforming the broader market. This performance contrasts sharply with the 8.6% increase in the BSE Healthcare index and 3.7% fall in the BSE Sensex during the same period. The company's stock closed at ₹331 on the BSE on Thursday, with analysts maintaining a positive outlook on the stock's trajectory. Recent market data shows the stock has demonstrated strong momentum with resistance levels calculated at 26.42% for the month and average positive change of 4.56% based on previous trading month ranges.
As reported by The Economic Times, Artemis Medicare Services is implementing a comprehensive expansion plan to increase its hospital capacity significantly. The company currently operates 1,100 beds and is targeting nearly 2,000 operational beds by 2030. This expansion will be executed across multiple locations including Gurugram, Raipur and South Delhi over the next few years, with new facilities in the pipeline to drive earnings growth. The VIMHANS project in South Delhi is expected to provide another significant growth leg beyond FY28, with the proposed facility initially having 450 beds and a further 200 beds planned subsequently, expected to become operational in FY29.
According to Moneycontrol, Artemis Medicare Services reported strong financial results for the June 2026 quarter. The company's consolidated net sales reached ₹287.32 crore, up 12.69% year-on-year, while standalone net sales stood at ₹282.01 crore, up 12.89% year-on-year. The company's book value per share stands at ₹61.03, reflecting solid financial health and growth trajectory. Historical data shows consistent growth momentum with standalone March 2026 net sales at ₹273.79 crore, up 16.6% year-on-year, and consolidated March 2026 net sales at ₹279.23 crore, up 16.39% year-on-year.
According to The Economic Times, the newly operational Artemis Shanti Hospital in Raipur is expected to be a significant growth driver despite gradual earnings contribution. The 300-bed facility commenced operations in July and is projected to achieve operating break-even within 15-18 months as utilization levels improve. International patients, who generate higher average revenue per operating bed (ARPOB) than domestic counterparts, accounted for 27% of revenue in the June quarter and are expected to approach or exceed 30% in the September quarter. InCred Equities expects revenue and EBITDA to grow annually at 23% and 28% respectively between FY26 and FY28, supported by higher bed utilization and premium case mix.
According to The Economic Times, analysts have retained a 'buy' rating on the stock with over 30% higher target prices from the current closing price. The company's strong financial performance and ambitious expansion plans position it well for sustained growth. With resistance levels calculated at 26.42% for the month and average positive change of 4.56% based on previous trading month ranges, the stock continues to demonstrate strong technical momentum alongside its fundamental growth story.
